var data={"title":"Protamine sulfate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Protamine sulfate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6865?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=protamine-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Protamine sulfate: Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=protamine-sulfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Protamine sulfate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7255805\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Protamine sulfate can cause severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, and pulmonary hypertension. Risk factors include high dose or overdose, rapid administration, repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). Allergy to fish, previous vasectomy, and severe left ventricular dysfunction and abnormal preoperative pulmonary hemodynamics also may be risk factors. In patients with any of these risk factors, the risk to benefit of administration of protamine sulfate should be carefully considered. Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. Protamine sulfate should not be given when bleeding occurs without prior heparin use.  </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215167\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215140\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin overdosage, following <i>intravenous</i> administration (off-label dosing):</b> IV: Because blood heparin concentrations decrease rapidly <b>after</b> heparin administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows: See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">\n        <b>Neutralization Dose of Protamine for IV Heparin Overdosage (Caravati 2004)</b></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Time Elapsed</b></p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose of Protamine (mg) to Neutralize 100 units of Heparin</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Immediate</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to1.5</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60 min</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.5 to 0.75</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 h</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.25 to 0.375</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin overdosage, following <i>SubQ</i> injection (off-label dosing):</b> IV: 1 to 1.5 mg protamine per 100 units heparin; this may be done by a portion of the dose (eg, 25 to 50 mg) given slowly IV followed by the remaining portion as a continuous infusion over 8 to 16 hours (the expected absorption time of the SubQ heparin dose) (Caravati 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin neutralization (off-label use):</b> IV: Protamine dosage is determined by the dosage of heparin; 1 mg of protamine neutralizes ~100 units of heparin; maximum dose: 50 mg. If the aPTT remains elevated, may repeat dose at 0.5 mg of protamine for every 100 units of heparin. In cardiac surgery, a maximum dose of 3 mg/kg may be required to reverse large doses of heparin administered intraoperatively (Kincaid 2014; NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> When heparin is given as a continuous IV infusion, only heparin given in the preceding 2 to 3 hours should be considered when administering protamine. For example, a patient receiving heparin 1,250 units/hour will require ~30 mg of protamine for reversal of heparin given in the last 2 to 2.5 hours (ACCP [Garcia 2012]; NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracranial hemorrhage associated with heparin or LMWH (off-label use): </b>According to the Neurocritical Care Society/Society of Critical Care Medicine (NCS/SCCM [Frontera 2016]): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Heparin-mediated (full dose infusions)</i>: 1 mg protamine for every 100 units of heparin administered in the previous 2 to 3 hours; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If the aPTT remains elevated, consider administering 0.5 mg protamine for every 100 units of heparin. Consider reversal for prophylactic subcutaneous doses of heparin when aPTT is significantly prolonged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>LMWH-mediated (full therapeutic dose): </i>\n      <b>Note:</b> In patients receiving LMWH for prophylaxis (ie, not a full therapeutic dose), the NCS/SCCM guidelines suggest <i>against</i> reversal.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enoxaparin: </i>1 mg protamine for every 1 mg of enoxaparin (if enoxaparin administered within 8 hours) or 0.5 mg protamine for every 1 mg of enoxaparin (if enoxaparin administered within 8 to 12 hours); administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If life-threatening bleeding persists or patient has renal impairment, consider repeat dose of 0.5 mg protamine for every 1 mg of enoxaparin. <b>Note:</b> Protamine may not be needed if 3 to 5 half-lives have elapsed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dalteparin, nadroparin, and tinzaparin:</i> 1 mg protamine for every 100 anti-Xa units of LMWH administered in the past 3 to 5 half-lives; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If life-threatening bleeding persists or patient has renal impairment, consider repeat dose of 0.5 mg protamine for every 100 anti-Xa units of LMWH.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>LMWH overdose (off-label use): </b> IV: <b>Note:</b> Anti-Xa activity is never completely neutralized (maximum: ~60% to 75%). Excessive protamine doses may worsen bleeding potential.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enoxaparin (Lovenox prescribing information 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enoxaparin administered in &le;8 hours:</i> Dose of protamine should equal the dose of enoxaparin administered. Therefore, 1 mg of protamine sulfate neutralizes 1 mg of enoxaparin.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enoxaparin administered in &gt;8 hours or if it has been determined that a second dose of protamine is required (eg, if aPTT measured 2 to 4 hours after the first dose remains prolonged or if bleeding continues):</i> 0.5 mg of protamine sulfate for every 1 mg of enoxaparin administered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dalteparin or tinzaparin (Fragmin prescribing information, 2010; Innohep prescribing information, 2010): 1 mg protamine for each 100 anti-Xa units of dalteparin or tinzaparin; if PTT prolonged 2 to 4 hours after first dose (or if bleeding continues), consider additional dose of 0.5 mg for each 100 anti-Xa units of dalteparin or tinzaparin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215156\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=protamine-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Protamine sulfate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin or enoxaparin neutralization (off-label use):</b> Limited data available: Infants, Children, and Adolescents: IV: Protamine dosage is determined by the most recent dosage of heparin or low molecular weight heparin (LMWH); 1 mg of protamine sulfate neutralizes ~100 units of heparin or 1 mg of enoxaparin; maximum protamine dose: 50 mg/dose. Dosing extrapolated from experience in adult patients (ACCP [Monagle 2012]; Lovenox prescribing information 2013; Park 2014). <b>Note:</b> When heparin is given as a continuous IV infusion, only heparin given in the preceding several hours (eg, 2 hours) should be considered when administering protamine (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin overdosage following <i>intravenous</i> administration (off-label use):</b> Limited data available (ACCP [Monagle 2012]): Infants, Children, and Adolescents: Because blood heparin concentrations decrease rapidly <b>after</b> heparin administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows (see table):</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">\n        <b>Neutralization Dose of Protamine for IV Heparin Overdosage in Pediatric Patients (Monagle 2012)</b></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Time Since Last Heparin Dose (min)</b></p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose of Protamine (mg) to Neutralize 100 units of Heparin</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;30</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.5 to 0.75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 120</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.375 to 0.5</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;120</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.25 to 0.375</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin overdosage following <i>SubQ</i> administration (off-label use)</b>: Limited data available: Infants, Children, and Adolescents: 1 to 1.5 mg protamine per 100 units heparin; this may be done by administering a portion of the protamine dose (eg, 25 to 50 mg) slowly IV followed by the remaining portion as a continuous infusion over 8 to 16 hours (the expected absorption time of the SubQ heparin dose) (Caravati 2004); dosing extrapolated from experience in adult patients (ACCP [Monagle 2012]; Park 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>LMWH overdosage (enoxaparin, dalteparin) (off-label use):</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Anti-Xa activity is never completely neutralized (maximum: ~60% to 75%). Excessive protamine doses may worsen bleeding potential; dosing extrapolated from experience in adult patients (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enoxaparin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enoxaparin dose administered &le;8 hours:</i> IV: Dose of protamine should equal the dose of enoxaparin administered; therefore, 1 mg protamine sulfate neutralizes per 1 mg of enoxaparin (Lovenox prescribing information 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enoxaparin administered &gt;8 hours prior or if it has been determined that a second dose of protamine is required (eg, if aPTT measured 2 to 4 hours after the first dose remains prolonged or if bleeding continues):</i> IV: 0.5 mg protamine sulfate for every 1 mg enoxaparin (Lovenox prescribing information 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dalteparin: IV: 1 mg protamine for each 100 anti-Xa units of dalteparin; if PTT prolonged 2 to 4 hours after first dose (or if bleeding continues), consider additional dose of 0.5 mg for each 100 anti-Xa units of dalteparin (Fragmin prescribing information 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215141\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22548550\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22548551\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215125\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (5 mL, 25 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (5 mL, 25 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215111\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215128\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV use only. Administer slow IVP (50 mg over 10 minutes). Rapid IV infusion causes hypotension; maximum of 50 mg in any 10-minute period.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215126\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Heparin overdose:</b> Treatment of heparin overdosage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744618\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Heparin neutralization (adults); Intracranial hemorrhage associated with heparin or LMWH; Low molecular weight heparin (LMWH) overdose (adults); Additional off-label uses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215175\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protamine may be confused with ProAmatine, Protonix, Protopam</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215118\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, flushing, hypotension, sudden decrease of blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Lassitude</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pulmonary hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215131\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to protamine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215115\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heparin rebound: Heparin rebound associated with anticoagulation and bleeding has been reported to occur occasionally; symptoms typically occur 8-9 hours after protamine administration, but may occur as long as 18 hours later.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: May cause hypersensitivity reaction in patients (have epinephrine 1 mg/mL  and resuscitation equipment available). <b>[US Boxed Warning]: Hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, pulmonary vasoconstriction, and pulmonary hypertension may occur. Risk factors for such events include use of high doses or overdose, repeated doses, previous protamine administration (including protamine-containing drugs), fish allergy, vasectomy, severe left ventricular dysfunction, and abnormal preoperative pulmonary hemodynamics.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion reactions: Too rapid administration can cause severe hypotensive and anaphylactoid-like reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac surgery patients: May be ineffective in some patients following cardiac surgery despite adequate doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299956\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222615\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9831&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215121\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13801118\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Protamine sulfate may be used during delivery to reduce the risk of bleeding following maternal use of heparin or low molecular weight heparin (LMWH) (Bates,  2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20618193\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if protamine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering protamine to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215123\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Coagulation test, aPTT or ACT, cardiac monitor and blood pressure monitor required during administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215114\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Protamine, a highly alkaline protein molecule with a large positive charge, has weak anticoagulant activity when administered alone. When protamine is given in the presence of heparin (strongly acidic and negatively charged), a stable salt is formed and the anticoagulant activity of both drugs is nullified (Pai 2012). In the presence of LMWH, protamine incompletely reverses the antifactor Xa activity of LMWH (Makris 2000; Massonnet-Castel 1986; Racanelli 1985).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215130\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: Heparin neutralization: ~5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~7 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323746\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Protamine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (5 mL): $11.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038788\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Denpru (AR);</li>\n      <li>Prosulf (GB);</li>\n      <li>Protamina (ES);</li>\n      <li>Protamina solfato (IT);</li>\n      <li>Protamine Choay (FR);</li>\n      <li>Protamine Sulfate Injection (AU);</li>\n      <li>Protamine Sulphate (GB);</li>\n      <li>Protamine Sulphate Injection BP (AU);</li>\n      <li>Protamini Sulfas (FI);</li>\n      <li>Protaminsulfat (NO);</li>\n      <li>Protaminsulfat Novo (AT);</li>\n      <li>Protaminsulfat &rdquo;Leo&rdquo; (DE, DK);</li>\n      <li>Protaminum Sulfuricum (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aren C, &ldquo;Heparin and Protamine Therapy,&rdquo; <i>Semin Thorac Cardiovasc Surg</i>, 1990, 2(4):364-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/2091796/pubmed\" target=\"_blank\" id=\"2091796\">2091796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e691-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caravati EM. Protamine sulfate. <i>Medical Toxicology</i>. 3rd ed. Dart RC, ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004;243-244.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15186641\"></a>Chawla LS, Moore G, Seneff MG. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. <i>Obesity Surg</i>. 2004;14(5):695-698.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/15186641/pubmed\" target=\"_blank\" id=\"15186641\">15186641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Brown JR, Despotis GJ, et al; Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion; International Consortium for Evidence Based Perfusion. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. <i>Ann Thorac Surg</i>. 2011;91(3):944-982.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/21353044/pubmed\" target=\"_blank\" id=\"21353044\">21353044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaherty ML, &ldquo;Anticoagulant-Associated Intracerebral Hemorrhage,&rdquo; <i>Semin Neuro</i>, 2010, 30(5):565-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/21207349/pubmed\" target=\"_blank\" id=\"21207349\">21207349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fragmin prescribing information, Pfizer Inc., New York, NY. October 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22315264\"></a>Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horrow JC, &ldquo;Protamine: A Review of Its Toxicity,&rdquo; <i>Anesth Analg</i>, 1985, 64(3):348-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/3883848/pubmed\" target=\"_blank\" id=\"3883848\">3883848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Innohep prescribing information, LEO Pharma Inc., Parsippany, NJ. May 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaques LB, &ldquo;Protamine - Antagonist to Heparin,&rdquo; <i>Can Med Assoc J</i>, 1973, 108(10):1291-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/4122234/pubmed\" target=\"_blank\" id=\"4122234\">4122234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kincaid EH, Hammon JW. Cardiopulmonary Bypass. In: Yuh DD, Varicella LA, Yang SC, Doty JR. eds. <i>Johns Hopkins Textbook of Cardiothoracic Surgery.</i> 2nd ed. New York, NY: McGraw-Hill; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kondo NI, Maddi R, Ewenstein BM, et al, &ldquo;Anticoagulation and Hemostasis in Cardiac Surgical Patients,&rdquo; <i>J Card Surg</i>, 1994, 9(4):443-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/7949674/pubmed\" target=\"_blank\" id=\"7949674\">7949674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindblad B, &ldquo;Protamine Sulfate: A Review of Its Effects - Hypersensitivity and Toxicity,&rdquo; <i>Eur J Vasc Surg</i>, 1989, 3(3):195-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/2663545/pubmed\" target=\"_blank\" id=\"2663545\">2663545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2827339\"></a>Lindblad B, Borgstr&ouml;m A, Wakefield TW, Whitehouse WM Jr, Stanley JC. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. <i>Thromb Res</i>. 1987;48(1):31-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/2827339/pubmed\" target=\"_blank\" id=\"2827339\">2827339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovenox prescribing information, Sanofi-Aventis U.S. LLC, Bridgewater, NJ. April 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10858037\"></a>Makris M, Hough RE, and Kitchen S, et al, &ldquo;Poor Reversal of Low Molecular Weight Heparin by Protamine,&rdquo; <i>Br J Haematol</i>, 2000, 108(4): 884-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/10858037/pubmed\" target=\"_blank\" id=\"10858037\">10858037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3710291\"></a>Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. <i>Haemostasis</i>. 1986;16(2):139-146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/3710291/pubmed\" target=\"_blank\" id=\"3710291\">3710291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan AK, Goldenberg NA, et al; American College of Chest Physicians. Antithrombotic therapy inneonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in <i>Chest</i>. 2014;146(5):1422 and <i>Chest</i>. 2014;146(6):1694]. <i>Chest</i>. 2012;141(2 suppl):e737S-801S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22566228\"></a>Pai M, Crowther MA. Neutralization of heparin activity. <i>Handb Exp Pharmacol</i>. 2012;(207):265-277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22566228/pubmed\" target=\"_blank\" id=\"22566228\">22566228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Protamine [prescribing information]. Lake Zurich, IL: Fresenius Kabi; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Racanelli A, Fareed J, Walenga JM, Coyne E. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. <i>Semin Thromb Hemost</i>. 1985;11(2):176-189.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/4035365/pubmed\" target=\"_blank\" id=\"4035365\">4035365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8958606\"></a>Wakefield TW and Stanley JC, &ldquo;Intraoperative Heparin Anticoagulation and Its Reversal,&rdquo; <i>Semin Vasc Surg</i>, 1996, 9(4):296-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/8958606/pubmed\" target=\"_blank\" id=\"8958606\">8958606</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9831 Version 112.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7255805\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F215167\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F215140\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F215156\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F215141\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22548550\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22548551\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F215125\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F215111\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F215128\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F215126\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744618\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F215175\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215118\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215131\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215115\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299956\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222615\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215121\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13801118\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20618193\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F215123\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215114\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F215130\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323746\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038788\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9831|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=protamine-sulfate-patient-drug-information\" class=\"drug drug_patient\">Protamine sulfate: Patient drug information</a></li><li><a href=\"topic.htm?path=protamine-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">Protamine sulfate: Pediatric drug information</a></li></ul></div></div>","javascript":null}